Financial Performance - Revenues for the three months ended September 30, 2025, were $581,000, a decrease of $48.8 million (98.8%) compared to $49.4 million in 2024 [181]. - Revenues for the nine months ended September 30, 2025, were $25.3 million, down $24.9 million (50%) from $50.2 million in 2024 [181]. - A net loss of $85.5 million was reported, adjusted for non-cash expenses, with significant changes in liabilities and assets impacting cash flow [213]. Research and Development - The Phase 1/2 STAND study for ST-503, an investigational epigenetic regulator for chronic neuropathic pain, has commenced patient enrollment and recruitment [168]. - A positive mean annualized estimated glomerular filtration rate (eGFR) slope of 1.965 mL/min/1.73m²/year was observed across all 32 dosed patients in the registrational Phase 1/2 STAAR study for isaralgagene civaparvovec, a gene therapy for Fabry disease [168]. - The company expects research and development expenses to increase in the near term due to activities related to the Fabry disease program [189]. Liquidity and Capital Resources - As of September 30, 2025, the company's cash and cash equivalents, along with the $6.0 million from Pfizer and $9.1 million generated through its at-the-market offering program, are estimated to be sufficient to meet liquidity requirements only into the first quarter of 2026 [162]. - Cash and cash equivalents as of September 30, 2025, were $29.6 million, down from $41.9 million as of December 31, 2024 [200]. - The company has approximately $148.7 million remaining available under its Open Market Sale Agreement as of September 30, 2025 [201]. Operating Expenses - Research and development expenses for the three months ended September 30, 2025, were $28.1 million, an increase of $0.4 million (1%) compared to $27.7 million in 2024 [184]. - General and administrative expenses for the three months ended September 30, 2025, were $8.0 million, a decrease of $3.1 million (28%) from $11.0 million in 2024 [184]. - Total operating expenses for the nine months ended September 30, 2025, were $108.4 million, a decrease of $19.9 million (15%) compared to $128.2 million in 2024 [184]. Future Outlook and Concerns - The company has incurred significant losses and expects to continue doing so for at least the next several years as it continues its research and development activities [174]. - The company has substantial doubt about its ability to continue as a going concern for at least the next 12 months, primarily due to significant losses and dependence on additional financing [204]. - The company anticipates continuing to incur operating losses for several years and needs to raise substantial additional capital to fund operations and development [211]. Capital Raising Efforts - The company is actively seeking additional capital through strategic collaborations and other financing sources to support its operations and research [162]. - The company is engaged in discussions for a commercialization agreement for its Fabry disease program but has not yet secured a partner [204]. - The company may face challenges in raising additional capital due to macroeconomic conditions, including the ongoing conflict between Russia and Ukraine [206]. Compliance and Regulatory Matters - The company has been granted a 180-day extension until April 27, 2026, to regain compliance with the minimum bid price requirement on The Nasdaq Capital Market [161]. - The company is preparing for a Biologics License Application (BLA) submission for isaralgagene civaparvovec as early as the first quarter of 2026 [171]. - Future capital requirements could exceed hundreds of millions of dollars per product for regulatory approvals from the FDA [206].

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

Financial Performance - Sangamo Therapeutics reported a consolidated net loss of $34.9 million, or $0.11 per share, for Q3 2025, compared to a net income of $10.7 million, or $0.04 per share, in Q3 2024[9]. - Revenues for Q3 2025 were $0.6 million, a decrease of $48.8 million from $49.4 million in Q3 2024, primarily due to the collaboration agreement with Genentech recorded in the previous year[11]. - Total operating expenses on a GAAP basis for Q3 2025 were $36.1 million, down from $38.8 million in Q3 2024, driven by lower personnel costs and licensing expenses[12][13]. - Revenues for Q3 2025 were $581 thousand, a significant decrease from $49,412 thousand in Q3 2024[26]. - Total operating expenses for Q3 2025 were $36,134 thousand, compared to $38,781 thousand in Q3 2024, reflecting a reduction in costs[26]. - Research and development expenses for the nine months ended September 30, 2025, were $81,232 thousand, down from $87,846 thousand in the same period of 2024[26]. - The net loss for Q3 2025 was $34,930 thousand, compared to a net income of $10,672 thousand in Q3 2024[26]. - The company reported a loss from operations of $35,553 thousand in Q3 2025, compared to an income of $10,631 thousand in Q3 2024[26]. Cash and Assets - Cash and cash equivalents as of September 30, 2025, were $29.6 million, down from $41.9 million as of December 31, 2024[14]. - Cash and cash equivalents as of September 30, 2025, were $29,616 thousand, a decrease from $41,918 thousand at the end of 2024[27]. - Total assets decreased to $88,643 thousand as of September 30, 2025, from $101,635 thousand at the end of 2024[27]. - Total stockholders' equity fell to $6,243 thousand as of September 30, 2025, down from $22,770 thousand at the end of 2024[27]. Future Outlook - The company expects total operating expenses in 2025 to be in the range of approximately $135 million to $155 million on a GAAP basis[15]. - Non-GAAP total operating expenses for 2025 are projected to be approximately $125 million to $145 million, excluding estimated non-cash stock-based compensation and depreciation[16]. - Sangamo's financial guidance for 2025 remains contingent on securing adequate additional funding[22]. Research and Development - Sangamo is preparing for a potential Biologics License Agreement (BLA) submission for isaralgagene civaparvovec as early as Q1 2026[10]. - The Phase 1/2 STAND study for chronic neuropathic pain has commenced patient enrollment, with the first patient expected to be dosed in the coming months[10]. - The mean annualized eGFR slope observed in the STAAR study for Fabry disease was 1.965 mL/min/1.73m²/year at 52 weeks across 32 patients[6]. - Sangamo is exploring collaborations and partnerships to advance its Fabry disease program and other initiatives[21]. Other Income - Sangamo received $6 million from Pfizer for the exercise of a buyout option related to a 2008 license agreement[6].

Core Insights - The company is advancing its clinical pipeline, particularly focusing on isaralgagene civaparvovec for Fabry disease, with a meeting held with the FDA to discuss the use of eGFR slope as an endpoint for accelerated approval [1][12] - The registrational STAAR study has shown promising clinical data, indicating that isaralgagene civaparvovec may provide durable treatment benefits for Fabry disease, with patient recruitment ongoing for the Phase 1/2 STAND study in chronic neuropathic pain [2][4] - Financial results for Q3 2025 show a significant decrease in revenues and a net loss, with total revenues of $0.6 million compared to $49.4 million in Q3 2024, primarily due to a collaboration agreement with Genentech recorded in the previous year [9][10] Clinical Developments - The STAAR study reported a positive mean annualized eGFR slope of 1.965 mL/min/1.73m²/year at 52 weeks across 32 patients, indicating the treatment's effectiveness [6] - Improvements in disease severity were noted, with 22 patients showing enhancements in their total MSSI score at 12 months [7] - The company is preparing for a potential Biologics License Agreement (BLA) submission for isaralgagene civaparvovec as early as Q1 2026 [12] Financial Performance - The consolidated net loss for Q3 2025 was $34.9 million, or $0.11 per share, compared to a net income of $10.7 million, or $0.04 per share, in Q3 2024 [9][29] - Total operating expenses for Q3 2025 were $36.1 million, a decrease from $38.8 million in the same period in 2024, driven by lower personnel costs and licensing expenses [13][14] - As of September 30, 2025, cash and cash equivalents stood at $29.6 million, down from $41.9 million at the end of 2024, with expectations to fund operations into Q1 2026 [15][30] Regulatory and Corporate Updates - The company held a productive interaction with the Medicines and Healthcare products Regulatory Agency (MHRA) regarding a prion disease study, anticipating a Clinical Trial Application (CTA) submission [3][12] - A $6 million payment was received from Pfizer for a buyout option related to a 2008 license agreement, enhancing the company's financial position [6] - The company continues to focus on establishing partnerships for the commercialization of its Fabry disease program while advancing its neurology pipeline [17][21]

Core Insights - Sangamo Therapeutics, Inc. is set to release its third quarter 2025 financial results on November 6, 2025, before market opening [1] - A conference call will be held at 8:30 a.m. Eastern on the same day to discuss financial results and provide business updates [1] Company Overview - Sangamo Therapeutics is focused on genomic medicine, aiming to develop treatments for serious neurological diseases lacking adequate treatment options [4] - The company utilizes zinc finger epigenetic regulators and a capsid discovery platform to potentially address neurological disorders and expand delivery methods [4] - Sangamo's pipeline includes multiple partnered programs and opportunities for further partnerships and investments [4]

Core Insights - The data supports the potential of isaralgagene civaparvovec as a one-time, durable treatment for Fabry disease, offering significant multi-organ clinical benefits compared to current care standards [1][6] - The STAAR study showed a positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52 weeks across all patients, which the FDA has agreed will be the primary basis for approval [1][6] - Sangamo plans to submit a Biologics License Application (BLA) in 2026 under the Accelerated Approval pathway [1][6] Efficacy - The STAAR study included 32 dosed patients with a positive mean annualized eGFR slope of 1.965 mL/min/1.73m/year at 52 weeks, which is favorable compared to approved Fabry treatments [4] - At Week 104, a mean annualized eGFR slope of 1.747 mL/min/1.73m/year was observed for 19 patients [4] - Stable cardiac function was maintained over at least one year, with various cardiac metrics remaining stable [4] Safety - Isaralgagene civaparvovec demonstrated a favorable safety and tolerability profile, with most adverse events being grade 1-2 [12] - The most common treatment-emergent adverse events included pyrexia (60.6%), COVID-19 (36.4%), headache (30.3%), and nasopharyngitis (33.3%) [12] - All treatment-emergent adverse events resolved with clinical management, and there were no safety-related study discontinuations or deaths [12] Regulatory Designations - Isaralgagene civaparvovec has received Orphan Drug, Fast Track, and RMAT designations from the FDA, as well as Orphan Medicinal Product designation from the European Medicines Agency [8] - The company is preparing for BLA submission while engaging in business development for potential commercialization [8] Study Design - The Phase 1/2 STAAR study is a global open-label, single-dose, dose-ranging, multicenter clinical study designed to evaluate isaralgagene civaparvovec in Fabry disease patients [10] - The study enrolled male and female patients, with a median age of 42 and a median follow-up duration of 24 months [7] Quality of Life Improvements - Statistically significant improvements in quality of life scores were observed, including role-physical (+14.8), vitality (+9.6), and bodily pain (+9.0) at week 52 compared to baseline [12] - Improvements in disease severity were reported in the Mainz Severity Score Index, with 22 patients showing total score improvements at 12 months [12]

Core Viewpoint - Sangamo Therapeutics (SGMO) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive outlook based on rising earnings estimates, which are a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Performance - The Zacks rating system emphasizes the correlation between changes in earnings estimates and stock price movements, suggesting that revisions in earnings estimates can lead to significant near-term price changes [4][6]. - For Sangamo, the Zacks Consensus Estimate has increased by 10% over the past three months, reflecting a positive trend in earnings expectations [8]. Zacks Rating System - The Zacks Rank system categorizes stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have averaged a +25% annual return since 1988 [7]. - Sangamo's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [10].

Financial Data and Key Metrics Changes - The company reported positive top-line results from the registrational STAR study in Fabry disease, with a mean annualized estimated glomerular filtration rate (eGFR) slope of almost 2 observed at 52 weeks across all 32 patients [7][8] - The FDA has agreed that the mean eGFR slope will serve as the primary basis for approval under the accelerated approval pathway [8][14] - The company completed an equity offering to bridge to an anticipated Fabry commercialization agreement, with the current cash runway expected to fund operations into 2025 [20] Business Line Data and Key Metrics Changes - The Fabry disease program showed a positive annualized eGFR slope of 1.7 for 19 patients who achieved two years of follow-up, compared to an average untreated decline of -3 to -4 [9][12] - The neurology pipeline program initiated its first clinical site for the Phase one/two STAND study in chronic neuropathic pain, with plans to dose the first patient in fall 2025 [15][19] Market Data and Key Metrics Changes - The company is engaging in business development negotiations for a potential Fabry commercialization agreement and broader discussions across its pipeline and platforms [20] - There is strong enthusiasm from both patients and physicians regarding the potential adoption of the Fabry treatment, with patients expressing a desire for better solutions compared to current standard care [40][41] Company Strategy and Development Direction - The company aims to secure a commercialization partner for its Fabry treatment while advancing its neurology genomic medicine pipeline [20] - The strategic focus includes addressing long-term funding needs to support the promising neurology pipeline and ensuring successful clinical trial outcomes [20] Management's Comments on Operating Environment and Future Outlook - Management expressed pride in the progress made despite a challenging environment, highlighting the importance of the recent clinical advancements [6][19] - The company anticipates preliminary proof of efficacy data for the STAND study in 2026 and is preparing for a BLA submission for the Fabry treatment as early as Q1 2026 [14][19] Other Important Information - The company held a productive meeting with the UK's MHRA regarding the prion disease program, aligning on planned studies and expected CTA submission by mid-2026 [16][17] - The company showcased its epigenetic regulation and capsid delivery technology at a recent conference, emphasizing the potential of its prion disease treatment [17] Q&A Session Summary Question: Has the team held the pre-BLA meeting with the FDA regarding the one-year eGFR data? - The company has not yet held the pre-BLA meeting but plans to do so in the future, with the FDA previously agreeing that one-year eGFR data could suffice for accelerated approval [24][25] Question: What additional insights should be anticipated at the upcoming presentation? - The company plans to present top-line data with additional details compared to previous releases, but individual patient data will not be shown [26][27] Question: How does the efficacy of ST-503 compare to recent small molecule Nav1.8 inhibitors? - Management remains convinced that targeting NaV1.7 is the right approach, citing evidence of its fundamental role in pain signaling [32][34] Question: Have any surveys been conducted to understand potential adoption rates for the Fabry treatment? - Feedback from patient advocacy groups indicates a strong desire for the treatment, with patients eager for a one-time injection solution compared to the burdensome current standard of care [39][40] Question: What is the status of discussions with potential partners? - All potential partners have expressed excitement about the data and are reassured by the company's interactions with the FDA, which have de-risked the product [43][45]

Neurology Focus and Technology - Sangamo is focused on developing genomic medicines for debilitating neurological diseases[3, 135] - The company utilizes potent zinc finger epigenetic regulation technology and an industry-leading AAV capsid discovery platform for brain delivery[4, 136] - STAC-BBB capsid has demonstrated robust penetration of the blood-brain barrier and widespread transgene expression throughout the brain in NHPs, showing up to 700-fold higher transgene expression than benchmark capsid AAV9[22, 24, 98] Pipeline and Milestones - Phase 1/2 STAND study of ST-503 for idiopathic small fiber neuropathy (iSFN) has initiated, with patient dosing expected in Fall 2025 and preliminary proof of efficacy data anticipated in Q4 2026[12, 16, 33, 38] - CTA submission for ST-506 in prion disease is anticipated as early as mid-2026, with clinical trial enrollment and dosing expected in late-2026 and preliminary clinical data in mid-2027[12, 19, 33, 38, 94] Fabry Disease Program - Positive topline results from the registrational STAAR study in Fabry disease showed a positive mean annualized eGFR slope of 1.965 mL/min/1.73m2/year at 52 weeks across all 32 dosed patients[12, 29, 33, 38, 131] - A BLA submission for isaralgagene civaparvovec is expected as early as Q1 2026, with ongoing business development negotiations for a potential commercialization agreement[12, 27, 33, 38, 130, 131] Financial Status - The company had approximately $38.3 million in cash and cash equivalents as of June 30, 2025[34, 40] - Approximately $21 million in net proceeds were raised from an underwritten registered equity offering[34, 38] - Cash received from partners to date is $88 million[25] - Up to $4.6 billion in potential future milestones and exercise fees assuming exercise of all options and targets[25]

PART I. FINANCIAL INFORMATION [Item 1. Financial Statements](index=7&type=section&id=Item%201.%20Financial%20Statements) The company presents unaudited financial statements reporting significant net losses and substantial doubt about its ability to continue as a going concern [Condensed Consolidated Balance Sheets](index=7&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) Condensed Consolidated Balance Sheet Highlights (in thousands) | Account | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $38,344 | $41,918 | | Total current assets | $49,893 | $51,691 | | Total assets | $97,558 | $101,635 | | **Liabilities & Equity** | | | | Total current liabilities | $47,659 | $45,805 | | Total liabilities | $77,956 | $78,865 | | Total stockholders' equity | $19,602 | $22,770 | [Condensed Consolidated Statements of Operations](index=8&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) Statements of Operations Highlights (in thousands, except per share amounts) | Metric | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | :--- | :--- | | Revenues | $18,306 | $356 | $24,743 | $837 | | Total operating expenses | $36,161 | $37,440 | $72,226 | $89,447 | | Loss from operations | ($17,855) | ($37,084) | ($47,483) | ($88,610) | | Net loss | ($19,986) | ($36,128) | ($50,583) | ($85,217) | | Basic and diluted net loss per share | ($0.08) | ($0.18) | ($0.21) | ($0.44) | [Condensed Consolidated Statements of Cash Flows](index=12&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Cash Flow Summary for Six Months Ended June 30 (in thousands) | Cash Flow Activity | 2025 | 2024 | | :--- | :--- | :--- | | Net cash used in operating activities | ($44,307) | ($75,547) | | Net cash (used in) provided by investing activities | ($24) | $35,967 | | Net cash provided by financing activities | $36,748 | $21,589 | | Net decrease in cash, cash equivalents, and restricted cash | ($3,574) | ($18,918) | [Notes to Condensed Consolidated Financial Statements](index=13&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) Notes detail accounting policies, revenue recognition, restructuring, and substantial doubt about the company's ability to continue as a going concern - Management has **substantial doubt** about the company's ability to continue as a going concern due to significant losses and limited liquidity[40](index=40&type=chunk)[41](index=41&type=chunk) - In April 2025, Sangamo entered a license agreement with Eli Lilly, receiving an **$18.0 million upfront payment** recognized as revenue in Q2 2025[83](index=83&type=chunk)[84](index=84&type=chunk)[88](index=88&type=chunk) - Pfizer terminated its collaboration agreement, resulting in a final **$5.0 million** in revenue recognized in the first half of 2025[109](index=109&type=chunk)[115](index=115&type=chunk) - The company undertook **significant restructuring**, including workforce reductions, to reduce costs and focus on neurology[140](index=140&type=chunk)[143](index=143&type=chunk) - A May 2025 underwritten offering generated aggregate net proceeds of **$21.1 million**[132](index=132&type=chunk)[133](index=133&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=30&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses the company's severe liquidity crisis, recent business highlights, and the urgent need for additional capital to continue operations [Overview and Recent Business Highlights](index=30&type=section&id=Overview%20and%20Recent%20Business%20Highlights) The company reports positive clinical data and recent financing but reiterates its 'going concern' risk with cash sufficient only into Q4 2025 - The company announced **positive topline results** from the Phase 1/2 STAAR study for its Fabry disease gene therapy and plans a BLA submission[161](index=161&type=chunk) - The company is advancing its preclinical neurology programs, with the first patient in its chronic neuropathic pain study expected to be dosed in **fall 2025**[158](index=158&type=chunk)[159](index=159&type=chunk) - The company continues to seek a collaboration partner for its hemophilia A program following the termination of its agreement with Pfizer[162](index=162&type=chunk) [Results of Operations](index=34&type=section&id=Results%20of%20Operations) Financial results show a significant revenue increase from a licensing deal, while restructuring efforts have reduced overall operating expenses Revenue Comparison (in thousands) | Period | 2025 | 2024 | Change | % Change | | :--- | :--- | :--- | :--- | :--- | | Three Months Ended June 30 | $18,306 | $356 | $17,950 | 5,042.1% | | Six Months Ended June 30 | $24,743 | $837 | $23,906 | 2,856.0% | - The revenue increase was primarily due to an **$18.0 million** upfront payment from the Lilly agreement and a **$5.0 million** payment from the terminated Pfizer collaboration[175](index=175&type=chunk)[176](index=176&type=chunk) Operating Expense Comparison (in thousands) | Expense Category | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | Change | % Change | | :--- | :--- | :--- | :--- | :--- | | Research and development | $53,090 | $60,114 | ($7,024) | (12%) | | General and administrative | $19,136 | $23,812 | ($4,676) | (20%) | | Impairment of long-lived assets | $0 | $5,521 | ($5,521) | (100%) | | **Total operating expenses** | **$72,226** | **$89,447** | **($17,221)** | **(19%)** | [Liquidity and Capital Resources](index=36&type=section&id=Liquidity%20and%20Capital%20Resources) The company details its severe liquidity constraints, with cash reserves sufficient only into Q4 2025, raising substantial doubt about its going concern status - As of June 30, 2025, the company had cash and cash equivalents of **$38.3 million**, down from $41.9 million at year-end 2024[193](index=193&type=chunk) - The company raised approximately **$21.1 million** from an underwritten offering and **$17.6 million** from its ATM program in the first half of 2025[194](index=194&type=chunk)[150](index=150&type=chunk) - Management concludes there is **substantial doubt** about the company's ability to continue as a going concern, as existing cash funds operations only into Q4 2025[197](index=197&type=chunk) [Item 3. Quantitative and Qualitative Disclosures about Market Risk](index=39&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20about%20Market%20Risk) As a smaller reporting company, this disclosure is not required [Item 4. Controls and Procedures](index=39&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were effective, with no material changes to internal controls during the quarter PART II. OTHER INFORMATION [Item 1. Legal Proceedings](index=41&type=section&id=Item%201.%20Legal%20Proceedings) The company is not currently a party to any material pending legal proceedings [Item 1A. Risk Factors](index=41&type=section&id=Item%201A.%20Risk%20Factors) Key risks include substantial doubt about going concern, potential Nasdaq delisting, and regulatory or trade policy disruptions - The company's financial position raises **substantial doubt** about its ability to continue as a going concern, risking cessation of operations or bankruptcy[218](index=218&type=chunk)[219](index=219&type=chunk) - Sangamo received a **Nasdaq deficiency notice** for its stock price falling below the $1.00 minimum bid requirement and faces potential delisting[225](index=225&type=chunk) - A new risk factor addresses potential **disruptions at the FDA**, which could adversely impact the Accelerated Approval pathway for its product candidates[234](index=234&type=chunk)[235](index=235&type=chunk) - The company identifies risks related to **international trade policies**, which could increase expenses and disrupt its supply chain[230](index=230&type=chunk)[231](index=231&type=chunk) [Items 2-6. Other Required Information](index=44&type=section&id=Items%202-6.%20Other%20Required%20Information) This section confirms no unregistered equity sales, defaults, or other material information, and lists the exhibits filed with the report